| Literature DB >> 31116057 |
Takuji Nakamura1,2, Tomomi Satoh-Nakamura1,2, Akio Nakajima2,3, Takafumi Kawanami2, Tomoyuki Sakai2, Yoshimasa Fujita2, Haruka Iwao2, Miyuki Miki2, Yasufumi Masaki2, Toshiro Okazaki2, Yasuhito Ishigaki4, Mitsuhiro Kawano5, Kazunori Yamada5, Shoko Matsui6, Takako Saeki7, Terumi Kamisawa8, Motohisa Yamamoto9, Hideaki Hamano10, Tomoki Origuchi11, Shintaro Hirata12,13, Yoshiya Tanaka12, Hiroto Tsuboi14, Takayuki Sumida14, Kazuichi Okazaki15, Masao Tanaka2,16, Tsutomu Chiba17, Tsuneyo Mimori16, Hisanori Umehara1,2.
Abstract
Background: IgG4-related disease (IgG4-RD) is characterized by elevated serum IgG4 and tissue infiltration by IgG4-positive plasma cells. The pathogenesis of this disease is not clear. Transcriptome analysis was performed to identify genes over- and under-expressed in patients with IgG4-RD.Method: DNA microarray analysis was performed using RNA from peripheral blood mononuclear cells of two patients with IgG4-RD and four healthy individuals. Genes showing a greater than threefold change in expression in IgG4-RD patients following steroid therapy were identified. Four genes related to innate immunity such as transcobalamin I (TCN1), secretory leukocyte peptidase inhibitor (SLPI), bactericidal/permeability-increasing protein (BPI) and lactotransferrin (LTF) were assessed by real-time PCR in 15 IgG4-RD patients and 13 healthy individuals.Result: DNA microarray analysis identified 30 genes showing a greater than threefold change in expression in IgG4-RD patients following steroid therapy. Real-time RT-PCR showed that the levels of mRNAs encoding TCNI and SLPI, except for BPI and LTF, were significantly lower in patients with IgG4-RD than in healthy people. The levels of all four mRNAs in patients with IgG4-RD were significantly increased after steroid treatment.Entities:
Keywords: DNA microarray analysis; IgG4-related disease; acquired immunity; innate immunity; innate immunity related gene
Year: 2019 PMID: 31116057 DOI: 10.1080/14397595.2019.1621475
Source DB: PubMed Journal: Mod Rheumatol ISSN: 1439-7595 Impact factor: 3.023